Latest Articles

  • Future-Proofing Pharmacovigilance in an AI Era

    Clinical research organizations (CROs) are entering an era in which pharmacovigilance systems are doing more than just tracking copious amounts of data. They must also keep pace with evolving regulations, manage the growing volume of adverse event reports, and respond to heightened scrutiny from both regulators and the public. read more

  • Prefilled Syringes: Sterile Drug Delivery, Market Dynamics, CDMO Partnerships, and Market Outlook to 2030

    The global pharmaceutical sterile and prefilled syringe market has experienced remarkable growth in recent years, fueled by technological advances and evolving therapeutic needs. read more

  • The Dog Days of Summer

    As I write this in the middle of August, during an oppressively humid heat wave, the term “the dog days of summer” comes to mind. If you have never heard that term, it refers to the hottest, most stifling period of summer. Quite apropos, as we are currently experiencing a heat wave. But where did the term come from? read more

  • A Critical Inflexion Point: The Indisputable Case for Next-Gen Pharmacovigilance

    Adverse event case processing is an enormous cost center and compliance issue for life sciences. As revenues stagnate for many pharma companies and profits come under new pressures, the expectation to improve its operational efficiency is substantial. But that cannot be at the expense of quality, or patient safety – the very purpose of pharmacovigilance. Organizations and their PV service providers have no choice but to take a smarter approach, underpinned by artificial intelligence and advanced automation. The cost and risk management benefits are clear, while the wider gains will include a more proactive PV operation, says Qinecsa’s John Cogan. read more